Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (6.069.750 €): PLATTFORM FÜR PRÄZISIONSMEDIZIN BEI NEURODEGENERATIVEN ERKRANKUNGEN Hor01.05.2023 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
PLATTFORM FÜR PRÄZISIONSMEDIZIN BEI NEURODEGENERATIVEN ERKRANKUNGEN
Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances in diagnostic technologies and the advent of disease-modifying therapies (DMT) for Alzheimer’s disease (AD), the most common aetiology of dementia, heralds the beginning of precision medicine in this disease area. PROMINENT will develop a digital platform for precision medicine that will remove barriers that currently exists for leveraging these technological advancements in the routine care of patients with neurodegenerative disorders and co-morbidities. The platform gives clinicians access to prediction models leveraging multimodal diagnostic data automatically derived from multiple sources (imaging repositories, medical records, mobile devices), helping them choose optimal care pathways and improving diagnostic precision. It will provide personalized, relevant and meaningful information on diagnosis and prognosis in a format understandable by patients and care partners. Further, it will support the introduction of new health technologies such as DMT for AD, by ensuring adherence to appropriate use guidelines and facilitating the prospective collection of data on real-world usage, safety and effectiveness. The expected impact of the project is to increase diagnostic accuracy and optimized use of existing and new treatment options. It will empower patients and caregivers by engaging them in more person-centric health care decisions, leading to improved adherence and patient experience. Ultimately this is expected to lead to cost-effective care, improved health outcomes and quality of life.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Alzheimer Europe | 398.750 € |
| Bioarctic AB | 0,00 € |
| CHU Hopitaux de Bordeaux | 173.375 € |
| Combinostics Oy | 0,00 € |
| Combinostics US Inc. | 0,00 € |
| Deutsches Zentrum FUR Neurodegenerative Erkrankungen e. V. | 26.250 € |
| Fundacio Barcelonabeta Brain Research Center | 435.875 € |
| IHE, Institutet FOR Halso- och Sjukvardsekonomi AB | 357.250 € |
| ITA-Suomen Yliopisto | 372.125 € |
| Karolinska Institutet | 1.811.375 € |
| Klinikum DER Universitaet ZU Koeln | 558.375 € |
| Oslo Universitetssykehus HF | 157.500 € |
| Region Hovedstaden | 157.500 € |
| Region Stockholm | 462.125 € |
| Stichting Amsterdam UMC | 302.125 € |
| Stiftelsen Fingers Brain Health Institute | 0,00 € |
| Synapse Research Management Partners SL | 555.000 € |
| Univerzitetni Klinicni Center Ljubljana | 302.125 € |
Quelle: https://cordis.europa.eu/project/id/101112145
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
